^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SL-901

    i
    Other names: SL-901, SL901
    Associations

    News

    Trials
    Company:
    Menarini, UCB
    Drug class:
    PI3K inhibitor, PIK3CA inhibitor, PI3Kδ inhibitor, DNA PK inhibitor, PIK3C2B inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=20, Completed, Stemline Therapeutics, Inc. | Recruiting --> Completed | N=60 --> 20 | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> May 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    SL-901